Cephalon founder Frank Baldino, Jr., Ph.D., has led the company from a privately held start-up to one the top ten biotechnology companies in the world. Dr. Baldino received his Ph.D. in pharmacology from Temple University. From 1981-1987, he served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research, and Brain Research. He chairs the Executive Council of the Harvard Division of Sleep Medicine and is a member of the Board of Trustees at Temple University and The Franklin (formerly known as The Franklin Institute). In addition, Dr. Baldino serves as a member of the Board of Directors for the Greater Philadelphia Chamber of Commerce, the Eastern Technology Council, PhRMA, BioAdvance Biotechnology Greenhouse Corp., Quaker BioVentures, L.P., and Pennsylvania BIO. He is also a member of the Board of Directors for NicOx, S.A., Pharmacopeia Drug Discovery, Inc. and Acusphere, Inc. Dr. Baldino is a member of the Healthcap Advisors Board and the MPM Capital and Vantage Point Venture Partners Advisory Committee. He also holds several adjunct academic appointments and serves on the Muhlenberg College Board of Observers.
